Dynamic alterations in linear growth and endocrine parameters in children with obesity and height reference values. (July 2021)
- Record Type:
- Journal Article
- Title:
- Dynamic alterations in linear growth and endocrine parameters in children with obesity and height reference values. (July 2021)
- Main Title:
- Dynamic alterations in linear growth and endocrine parameters in children with obesity and height reference values
- Authors:
- Kempf, Elena
Vogel, Mandy
Vogel, Tim
Kratzsch, Jürgen
Landgraf, Kathrin
Kühnapfel, Andreas
Gausche, Ruth
Gräfe, Daniel
Sergeyev, Elena
Pfäffle, Roland
Kiess, Wieland
Stanik, Juraj
Körner, Antje - Abstract:
- Abstract: Background: Obesity can affect linear growth of children but there is uncertainty regarding the dynamics and potential causes. Methods: In the population-based LIFE Child and the obesity-enriched Leipzig Obesity Childhood cohorts (8, 629 children, 37, 493 measurements), recruited from 1999 to 2018 in Germany, we compared height, growth, and endocrine parameters between normal-weight and children with obesity (0–20 years). Derived from the independent German CrescNet registry (12, 703 children) we generated height reference values specific for children with obesity (data collected from 1999 to 2020). Findings: Children with obesity were significantly taller than normal-weight peers, differing at maximum by 7·6 cm (1·4 height, standard deviation scores or SDS) at age 6–8 years. Already at birth, children with obesity were slightly taller and thereafter had increased growth velocities by up to 1·2 cm/year. This growth acceleration was unrelated to parental height, but was accompanied by increased levels of insulin-like growth factor-1 (IGF-1), insulin and leptin. During puberty, children with obesity showed a catch-down in height SDS. The reduction in pubertal growth velocity by up to 25% coincided with a decrease in levels of IGF-1 (by 17%) and testosterone (by 62%) in boys and estradiol (by 37%) in girls. We confirmed these alterations in growth in the independent CrescNet cohort and furthermore provide height reference values for children with obesity for openAbstract: Background: Obesity can affect linear growth of children but there is uncertainty regarding the dynamics and potential causes. Methods: In the population-based LIFE Child and the obesity-enriched Leipzig Obesity Childhood cohorts (8, 629 children, 37, 493 measurements), recruited from 1999 to 2018 in Germany, we compared height, growth, and endocrine parameters between normal-weight and children with obesity (0–20 years). Derived from the independent German CrescNet registry (12, 703 children) we generated height reference values specific for children with obesity (data collected from 1999 to 2020). Findings: Children with obesity were significantly taller than normal-weight peers, differing at maximum by 7·6 cm (1·4 height, standard deviation scores or SDS) at age 6–8 years. Already at birth, children with obesity were slightly taller and thereafter had increased growth velocities by up to 1·2 cm/year. This growth acceleration was unrelated to parental height, but was accompanied by increased levels of insulin-like growth factor-1 (IGF-1), insulin and leptin. During puberty, children with obesity showed a catch-down in height SDS. The reduction in pubertal growth velocity by up to 25% coincided with a decrease in levels of IGF-1 (by 17%) and testosterone (by 62%) in boys and estradiol (by 37%) in girls. We confirmed these alterations in growth in the independent CrescNet cohort and furthermore provide height reference values for children with obesity for open access. Interpretation: Dynamics of linear growth are altered distinctively in different developmental phases in children with obesity. Early emergence before other profound comorbidities implies predisposition, environmental, and/or endocrine factors affecting growth in early life. Height reference values for children with obesity may enhance the precision of clinical health surveillance. Funding: German Research Foundation, German Diabetes Association, EU, ESF, ERDF, State of Saxony, ESPE, Hexal, Novo Nordisk, Pfizer Pharma. … (more)
- Is Part Of:
- EClinicalMedicine. Volume 37(2021)
- Journal:
- EClinicalMedicine
- Issue:
- Volume 37(2021)
- Issue Display:
- Volume 37, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 37
- Issue:
- 2021
- Issue Sort Value:
- 2021-0037-2021-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-07
- Subjects:
- Children -- Obesity -- Height -- Growth velocity -- IGF-1 -- Insulin -- Leptin -- Estradiol -- Testosterone
Medicine -- Research -- Periodicals
Medical policy -- Periodicals
Clinical Medicine
Health Policy
Public Health
Medical policy
Medicine -- Research
Periodical
Electronic journals
Periodicals
613 - Journal URLs:
- https://www.sciencedirect.com/science/journal/25895370 ↗
http://www.sciencedirect.com/ ↗ - DOI:
- 10.1016/j.eclinm.2021.100977 ↗
- Languages:
- English
- ISSNs:
- 2589-5370
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 17784.xml